HK1212977A1 - 苯達莫司汀衍生物及其使用方法 - Google Patents

苯達莫司汀衍生物及其使用方法

Info

Publication number
HK1212977A1
HK1212977A1 HK16100891.2A HK16100891A HK1212977A1 HK 1212977 A1 HK1212977 A1 HK 1212977A1 HK 16100891 A HK16100891 A HK 16100891A HK 1212977 A1 HK1212977 A1 HK 1212977A1
Authority
HK
Hong Kong
Prior art keywords
methods
same
bendamustine
bendamustine derivatives
derivatives
Prior art date
Application number
HK16100891.2A
Other languages
English (en)
Inventor
P Bakale Roger
d brown Peter
Chen Jian
S Drager Anthony
Y Labell Rachel
E Mckean Robert
R Patel Piyush
C Roemmele Renee
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of HK1212977A1 publication Critical patent/HK1212977A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
HK16100891.2A 2012-11-12 2016-01-27 苯達莫司汀衍生物及其使用方法 HK1212977A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201361776951P 2013-03-12 2013-03-12
PCT/US2013/069550 WO2014075035A1 (en) 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same

Publications (1)

Publication Number Publication Date
HK1212977A1 true HK1212977A1 (zh) 2016-06-24

Family

ID=49667594

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16100090.1A HK1215701A1 (zh) 2012-11-12 2016-01-06 苯達莫司汀衍生物及其使用方法
HK16100891.2A HK1212977A1 (zh) 2012-11-12 2016-01-27 苯達莫司汀衍生物及其使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16100090.1A HK1215701A1 (zh) 2012-11-12 2016-01-06 苯達莫司汀衍生物及其使用方法

Country Status (17)

Country Link
US (7) US9452988B2 (zh)
EP (1) EP2917183A1 (zh)
JP (1) JP6262246B2 (zh)
KR (1) KR20150086308A (zh)
AR (1) AR093457A1 (zh)
AU (1) AU2013342015B2 (zh)
BR (1) BR112015010501A2 (zh)
CA (1) CA2890462A1 (zh)
CL (1) CL2015001246A1 (zh)
EA (1) EA029706B1 (zh)
HK (2) HK1215701A1 (zh)
IL (1) IL238662A (zh)
MX (1) MX2015005805A (zh)
PH (1) PH12015501024A1 (zh)
SG (1) SG11201503560TA (zh)
TW (1) TWI598341B (zh)
WO (1) WO2014075035A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
EP2917183A1 (en) 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
US9598377B2 (en) 2013-03-12 2017-03-21 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018013783A1 (en) * 2016-07-13 2018-01-18 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP2004518776A (ja) * 2000-12-01 2004-06-24 エンゾン，インコーポレーテッド テトラパルテートプロドラッグ
WO2003086369A2 (en) * 2002-04-05 2003-10-23 Valorisation-Recherche, Societe En Commandite Stealthy polymeric biodegradable nanospheres and uses thereof
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
ES2535217T3 (es) * 2007-11-28 2015-05-07 Celator Pharmaceuticals, Inc. Sistema mejorado de administración de taxano
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
CA2738855A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
AU2009302493B2 (en) 2008-10-08 2015-04-09 Cephalon Llc Processes for the preparation of bendamustine
MX2011005643A (es) * 2008-12-03 2011-09-27 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
DK2575784T3 (en) 2010-06-02 2018-10-15 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
DE102010055499A1 (de) 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
WO2012158776A2 (en) 2011-05-17 2012-11-22 University Of South Alabama Combination therapy for treatment of cancer
WO2013046223A1 (en) 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
ES2535511T3 (es) 2012-04-26 2015-05-12 Helmut Schickaneder Ésteres de bendamustina y compuestos relacionados, y uso médico de los mismos
MX365192B (es) 2012-06-19 2019-05-23 Synbias Pharma Ag Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
US9314532B2 (en) 2012-08-10 2016-04-19 University Of North Texas Health Science Center Drug delivery vehicle
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same

Also Published As

Publication number Publication date
EP2917183A1 (en) 2015-09-16
KR20150086308A (ko) 2015-07-27
EA029706B1 (ru) 2018-05-31
US9149464B2 (en) 2015-10-06
SG11201503560TA (en) 2015-06-29
BR112015010501A2 (pt) 2017-07-11
IL238662A0 (en) 2015-06-30
US9913827B2 (en) 2018-03-13
WO2014075035A1 (en) 2014-05-15
JP6262246B2 (ja) 2018-01-17
US9452988B2 (en) 2016-09-27
CN105051016A (zh) 2015-11-11
IL238662A (en) 2017-08-31
JP2015536996A (ja) 2015-12-24
TW201439069A (zh) 2014-10-16
EA201590925A1 (ru) 2015-09-30
US20160016912A1 (en) 2016-01-21
US20180147186A1 (en) 2018-05-31
US9630926B2 (en) 2017-04-25
US20170182008A1 (en) 2017-06-29
US20150246023A1 (en) 2015-09-03
TWI598341B (zh) 2017-09-11
CL2015001246A1 (es) 2016-01-15
MX2015005805A (es) 2016-04-15
US20150232427A1 (en) 2015-08-20
US9150517B2 (en) 2015-10-06
CA2890462A1 (en) 2014-05-15
AU2013342015A1 (en) 2015-05-28
US20160289198A1 (en) 2016-10-06
AU2013342015B2 (en) 2016-11-24
PH12015501024A1 (en) 2015-07-27
HK1215701A1 (zh) 2016-09-09
US20150274675A1 (en) 2015-10-01
AR093457A1 (es) 2015-06-10

Similar Documents

Publication Publication Date Title
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HK1212977A1 (zh) 苯達莫司汀衍生物及其使用方法
HK1208439A1 (zh) -氮雜吲唑化合物及其使用方法
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
EP2938341A4 (en) Heterocyclic compounds and methods for the use thereof
EP2814487A4 (en) BENDAMUSTIN FORMULATIONS
EP2897855A4 (en) FOLDING BIKE AND METHOD OF USE
EP2806872A4 (en) BENDAMUSTIN COMPOSITIONS AND RELATED METHODS
FI2827862T3 (fi) Bendamustiinin formulaatioita
HK1222129A1 (zh) 脱氧野尻霉素衍生物及其使用方法
EP2919983A4 (en) ARTICLES WITH FIBER-REINFORCED POLYMERS AND METHOD OF USE THEREOF
HK1198833A1 (zh) -酰基肽衍生物及其應用
EP2904881A4 (en) ILLUMINATES AND METHOD FOR USE THEREOF
HK1204473A1 (zh) 製造和使用納米結構的方法
HK1205695A1 (zh) 副粘病毒和使用方法
IL234080A (en) Tetrazolylhydroxyimino derivatives and methods for their production
IL238934A0 (en) Methods for the preparation of phenyloxymethyl-nitro-imidazole derivatives and their use
EP2870133A4 (en) TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF
GB201222855D0 (en) Lock Means and Method of Use Thereof
GB201204455D0 (en) Barrier means and method of use thereof